J
Jennifer R. Skibbe
Researcher at University of Cincinnati
Publications - 8
Citations - 2879
Jennifer R. Skibbe is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 7, co-authored 8 publications receiving 1556 citations. Previous affiliations of Jennifer R. Skibbe include Beckman Research Institute & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
Recognition of RNA N 6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation
Huilin Huang,Huilin Huang,Hengyou Weng,Hengyou Weng,Wen-Ju Sun,Xi Qin,Xi Qin,Hailing Shi,Hailing Shi,Huizhe Wu,Huizhe Wu,Huizhe Wu,Boxuan Simen Zhao,Boxuan Simen Zhao,Ana Mesquita,Chang Liu,Chang Liu,Celvie L. Yuan,Yueh-Chiang Hu,Stefan Hüttelmaier,Jennifer R. Skibbe,Rui Su,Rui Su,Xiaolan Deng,Xiaolan Deng,Xiaolan Deng,Lei Dong,Lei Dong,Miao Sun,Chenying Li,Chenying Li,Chenying Li,Sigrid Nachtergaele,Sigrid Nachtergaele,Yungui Wang,Yungui Wang,Chao Hu,Chao Hu,Kyle Ferchen,Kenneth D. Greis,Xi Jiang,Xi Jiang,Minjie Wei,Liang-Hu Qu,Jun-Lin Guan,Chuan He,Chuan He,Jian-Hua Yang,Jianjun Chen,Jianjun Chen +49 more
TL;DR: This work reports the insulin-like growth factor 2 mRNA-binding proteins as a distinct family of m6A readers that target thousands of mRNA transcripts through recognizing the consensus GG(m6A)C sequence, and identifies IGF2BPs as an additional class of N6-methyladenosine (m 6A) reader proteins.
Journal ArticleDOI
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Rui Su,Lei Dong,Chenying Li,Sigrid Nachtergaele,Mark Wunderlich,Ying Qing,Xiaolan Deng,Yungui Wang,Yungui Wang,Xiaocheng Weng,Chao Hu,Chao Hu,Mengxia Yu,Jennifer R. Skibbe,Qing Dai,Dongling Zou,Tong Wu,Kangkang Yu,Hengyou Weng,Huilin Huang,Kyle Ferchen,Xi Qin,Bin Zhang,Jun Qi,Atsuo T. Sasaki,David R. Plas,James E. Bradner,Minjie Wei,Guido Marcucci,Xi Jiang,James C. Mulloy,Jie Jin,Chuan He,Jianjun Chen,Jianjun Chen +34 more
TL;DR: While R-2HG accumulated in IDH1/2 mutant cancers contributes to cancer initiation, this work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CEBPA signaling.
Journal ArticleDOI
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification
Hengyou Weng,Huilin Huang,Huizhe Wu,Xi Qin,Boxuan Simen Zhao,Lei Dong,Hailing Shi,Jennifer R. Skibbe,Chao Shen,Chao Hu,Chao Hu,Yue Sheng,Yungui Wang,Yungui Wang,Mark Wunderlich,Bin Zhang,Louis C. Dore,Rui Su,Xiaolan Deng,Xiaolan Deng,Kyle Ferchen,Chenying Li,Chenying Li,Miao Sun,Zhike Lu,Xi Jiang,Guido Marcucci,James C. Mulloy,Jian-Hua Yang,Zhijian Qian,Minjie Wei,Chuan He,Jianjun Chen +32 more
TL;DR: The results reveal the SPI1-METTL14-MYB/MYC signaling axis in myelopoiesis and leukemogenesis and highlight the critical roles of METTL14 and m6A modification in normal and malignant hematopoiedis.
Journal ArticleDOI
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Xi Jiang,Xi Jiang,Xi Jiang,Chao Hu,Chao Hu,Chao Hu,Kyle Ferchen,Ji Nie,Xiaolong Cui,Chih-Hong Chen,Liting Cheng,Zhixiang Zuo,Zhixiang Zuo,William L. Seibel,Chunjiang He,Yixuan Tang,Jennifer R. Skibbe,Mark Wunderlich,William C. Reinhold,Lei Dong,Lei Dong,Chao Shen,Chao Shen,Stephen Arnovitz,Bryan Ulrich,Jiuwei Lu,Hengyou Weng,Hengyou Weng,Hengyou Weng,Rui Su,Rui Su,Huilin Huang,Huilin Huang,Yungui Wang,Yungui Wang,Yungui Wang,Chenying Li,Chenying Li,Chenying Li,Xi Qin,Xi Qin,James C. Mulloy,Yi Zheng,Jiajie Diao,Jie Jin,Chong Li,Paul P. Liu,Chuan He,Yuan Chen,Jianjun Chen,Jianjun Chen,Jianjun Chen +51 more
TL;DR: Two compounds that target the binding of STAT3/5 specifically to the TET1 promoter, inhibiting its expression and AML cell viability are identified and highlight the therapeutic potential of targeting the STAT/TET1 axis by selective inhibitors in AML treatment.
Journal ArticleDOI
Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.
Chenying Li,Lei Dong,Rui Su,Ying Bi,Ying Qing,Xiaolan Deng,Yile Zhou,Chao Hu,Mengxia Yu,Hao Huang,Xi Jiang,Xia Li,Xiao He,Dongling Zou,Chao Shen,Li Han,Miao Sun,Jennifer R. Skibbe,Kyle Ferchen,Xi Qin,Hengyou Weng,Huilin Huang,Chun-Xiao Song,Jianjun Chen,Jie Jin +24 more
TL;DR: A previously unappreciated DNA epigenome-related mechanism underlying the potent antileukemic effect of homoharringtonine is uncovered, which involves suppression of the SP1/TET1/5hmC/FLT3/MYC signaling pathways in AML.